Uroplasty Reports Continued Progress During Second Quarter of F...(p marketing 2505598 1974...),Health

marketing 2,505,598 1,974,583 5,125,632 3,607,372

Amortization of

intangibles 210,966 206,482 421,941 423,003

3,962,936 3,755,494 8,238,179 6,919,303

Operating loss (591,619) (1,384,992) (1,049,207) (2,194,339)

Other income (expense)

Interest income 63,542 65,239 138,656 141,622

Interest expense (6,750) (9,279) (13,585) (20,644)

Foreign currency

exchange gain (loss) 5,038 (13,877) (732) (15,906)

Other, net (4,687) - (4,687) 1,880

57,143 42,083 119,652 106,952

Loss before income

taxes (534,476) (1,342,909) (929,555) (2,087,387)

Income tax expense 26,487 41,783 38,057 137,940

Net loss $(560,963) $(1,384,692) $(967,612) $(2,225,327)

Basic and diluted

loss per common

share $(0.04) $(0.10) $(0.06) $(0.17)

Weighted average

common shares

outstanding:

Basic and

diluted 14,916,540 13,342,284 14,916,540 13,162,862

UROPLASTY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

September 30, 2008 March 31, 2008

(unaudited)

Assets

Current assets:

Cash and cash equivalents and

short-term investments $9,024,697 $10,146,081

Accounts receivable, net 1,690,285 2,318,604

Income tax receivable 34,445 50,841

Inventories 527,460 558,657

Other
'/>"/>